[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-metastatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-metastatic":249},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,40,66,96,127,159,184,215,238,315,337,360],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100546154","phase-3-stereotactic-body-radiotherapy-vs-conventional-palliative-radiotherapy-for-painful-non-spine-bone-metastases-100546154",false,"NCT06391242","Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases","A Randomized Phase III Trial Comparing Stereotactic Body Radiotherapy to Conventional Palliative Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) for Participants With Painful Non-Spine Bone Metastases","Inclusion Criteria:\n\n* Histologic confirmation of solid tumour.\n* Patient with a dominant painful non-spine bone metastasis and a worst minimum pain score of 2 using the BPI attributed to that dominant site\n* Expected overall survival of greater than 6 months as determined by the treating physician\n* Suitable for protocol defined SBRT and CRT.\n* Stable pain with no immediate plan to alter analgesic regimen.\n* ECOG performance status of 0-2.\n* Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form prior to enrolment in the trial to document their willingness to participate\n\nExclusion Criteria:\n\n* Metastases of the hands, feet, cranium or spine (including sacrum) as the dominant\u002Findex pain site.\n* Bone metastasis arising from a small cell or germ cell.\n* Radionuclide therapy within 30 days of randomization.\n* Patient treated with prior palliative RT to the dominant painful bone metastasis site (prior radiation exposure is permitted if prior to development of the dominant metastasis and would not influence the applicability of either treatment arm of the current study).\n* Received systemic chemotherapy within 1 week of the protocol RT, or who are expected\u002Fplanned to receive chemotherapy within one week of completing protocol RT.\n* Participants with an unstable pathologic fracture at the dominant painful bone metastasis, or for whom surgical fixation would be the preferred intervention if possible.\n* Pregnant or lactating individuals.","ALL","18 Years",{"count":19,"type":20},230,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study is being done to answer the following question: Is Stereotactic Body Radiation Therapy or SBRT (a form of radiation therapy which can deliver high doses of radiation to the specific painful area of the body most affected by cancer, while keeping the radiation beams away from the healthy parts of the body that surround the cancer) better for pain relief than the standard treatment of conventional radiation therapy or CRT (a form of radiation therapy which delivers radiation to the painful area but can also negatively affect other parts of the body in the same area)",[26],"Cancer Metastatic","RECRUITING","2026-06-08",{"date":30,"type":31},"2026-06-09","ACTUAL",{"date":33,"type":31},"2025-03-07",{"date":35,"type":20},"2028-01-01",{"name":37,"class":38},"Canadian Cancer Trials Group","NETWORK",9,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100457116","phase-1-determine-safety--recommended-phase-2-dosing-of-zeaxanthin-alone-or-in-combination-wpembrolizumab-in-patients-with-metastatic-cancer-100457116","NCT05232409","Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w\u002FPembrolizumab in Patients With Metastatic Cancer","A Phase I Study to Determine the Safety and Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination With Pembrolizumab in Patients With Metastatic Solid Tumors","Inclusion Criteria for Dose escalation zeaxanthin monotherapy\n\n1. Stage IV or unresectable stage 3 histologically confirmed solid tumor malignancy refractory to all standard therapies known to provide clinical benefit (unless the therapy is contraindicated or intolerable) in the opinion of the treating investigator for his\u002Fher tumor type. Subjects are not required to have received systemic therapies that have response rates under 20% with no associated survival benefit (for example DTIC chemotherapy and high dose Interleukin-2 in melanoma patients).\n2. Age ≥ 18 years.\n3. Performance status ECOG 0, 1 or 2\n4. Adequate organ and marrow function as describe below:\n\n   * Absolute neutrophil count ≥ 1,500\u002FmcL\n   * Platelets ≥ 100,000\u002Fmcl\n   * Total bilirubin \\\u003C 1.5 x the normal institutional limits excluding patients with confirmed Gilbert's syndrome\n   * AST (SGOT)\u002FALT (SPGT) ≤ 3 x the institutional upper limit of normal (ULN)\n   * Creatinine ≤ 1.5 x the institutional upper limit of normal\n5. Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\n   Recommended methods of birth control are:\n   1. The consistent use of an approved hormonal contraception (birth control pill\u002Fpatches, rings), An intrauterine device (IUD), Contraceptive injection (Depo-Provera), Double barrier methods (Diaphragm with spermicidal gel or condoms with contraceptive foam), Sexual abstinence (no sexual intercourse) or Sterilization.\n   2. Men must agree to use a condom and not father a child or donate sperm for the duration of the study and for 90 days after completion of therapy\n\n   A Female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets at least one of the following criteria:\n   1. Has not undergone a hysterectomy or bilateral oophorectomy\n   2. Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n6. Ability to understand and the willingness to sign a written informed consent.\n7. Measurable disease is not required but evaluable disease is required.\n8. Life expectancy of at least 3 months\n\nExclusion Criteria for Dose escalation zeoxanthin monotherapy\n\n1. Patients who have had chemotherapy or radiotherapy within 21 days prior to initiating study treatment or those who have not recovered to grade 1 or less from adverse events due to agents administered more than 21 days earlier excluding alopecia, gd 2 fatigue, gd 2 hearing loss from platinum agent, and endocrinopathies on stable replacement therapy.\n\n   (Patients may not be receiving any other investigational agents or concomitant chemotherapy or radiation therapy. Hormonal therapy is not exclusionary.)\n2. Patients with active brain metastases requiring palliation with steroids and not stable for at least 4 weeks post radiation therapy or surgery.\n3. Leptomeningeal carcinomatosis\n4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to zeaxanthin.\n5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n6. Patients with another primary malignancy not in remission for at least 3 years. Exceptions include nonmelanoma skin cancer, curatively treated localized prostate cancer with normal prostate specific antigen, low risk prostate cancer followed expectantly, stage I colorectal cancer resected, resected stage 1 breast cancer cervical carcinoma in situ on biopsy, melanoma in situ resected, or squamous intraepithelial lesion on PAP smear.\n7. Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants. Women of child bearing potential must have a negative serum or urine pregnancy test prior to the first dose of study treatment\n8. Inability to swallow pills.\n\nInclusion Criteria for dose escalation zeoxanthin plus pembrolizumab\n\n1. Stage IV or unresectable stage 3 histologically confirmed solid tumor malignancy for which pembrolizumab is FDA approved and progressed on prior PD-1 or PD-L1 therapy and if indicated for cancer type refractory to all standard therapies known to provide clinical benefit (unless the therapy is contraindicated or intolerable) in the opinion of the treating investigator for his\u002Fher tumor type. Subjects are not required to have received systemic therapies that have response rates under 20% with no associated survival benefit (for example DTIC chemotherapy and high dose Interleukin-2 in melanoma patients).\n2. Patients must have had symptomatic or radiographic progression during or following treatment with a PD-1 or PD-L1 inhibitor. This is defined as imaging obtained subsequent to initiation of PD-1 or PD-L1 inhibitor demonstrating a new lesion that is consistent with metastasis or growth of a preexisting metastasis which the treating physician felt reflected tumor progression and therefore discontinued the immunotherapy. . Symptomatic progression refers to development of worsening bone pain related to bone metastasis that cannot be accurately measured on imaging and for which the treating physician had discontinued the immunotherapy.\n3. Age ≥ 18 years.\n4. Performance status ECOG 0, 1or 2.\n5. Adequate organ and marrow function as describe below:\n\n   * Absolute neutrophil count ≥ 1,500\u002FmcL\n   * Platelets ≥ 100,000\u002Fmcl\n   * Total bilirubin) ≤ 1.5 x normal institutional limits excluding patients with confirmed Gilbert's syndrome\n   * AST (SGOT)\u002FALT (SPGT) ≤ 3 x institutional upper limit of normal\n   * Creatinine ≤ 1.5 x the institutional upper limit of normal\n6. Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\n   Recommended methods of birth control are:\n   1. The consistent use of an approved hormonal contraception (birth control pill\u002Fpatches, rings), An intrauterine device (IUD), Contraceptive injection (Depo-Provera), Double barrier methods (Diaphragm with spermicidal gel or condoms with contraceptive foam), Sexual abstinence (no sexual intercourse) or Sterilization.\n   2. Men must agree to use a condom and not father a child or donate sperm for the duration of the study and for 90 days after completion of therapy\n\n   A Female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets at least one of the following criteria:\n   1. Has not undergone a hysterectomy or bilateral oophorectomy\n   2. Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n7. Ability to understand and the willingness to sign a written informed consent.\n8. Measurable disease is not required but evaluable disease is required\n9. Life expectancy of at least 3 months\n\nExclusion Criteria for zeoxanthin plus pembrolizumab\n\n1. Patients who have had immunotherapy, chemotherapy or radiotherapy within 21 days prior to entering the study or those who have not recovered to grade1 or lower from adverse events due to agents administered more than 21 days earlier excluding alopecia, gd 2 fatigue, gd 2 hearing loss from platinum agent, and endocrinopathies on stable replacement therapy.\n2. Prior grade 3 or greater immune mediated toxicity related to PD-1 or PD-L1 inhibitor. Prior grade 2 or higher colitis, diarrhea, hepatitis, neurologic, cardiac, immune mediated toxicity related to PD-1 or PD-L1 inhibitor. Exceptions include vitiligo and controlled endocrinopathies.\n3. Patients may not be receiving any other investigational agents or concomitant chemotherapy or radiation therapy.\n4. Patients taking oral steroids at or greater than the equivalent of 10 milligrams of oral prednisone daily.\n5. Inability to swallow pills.\n6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to zeaxanthin.\n7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n8. Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants. Women of child bearing potential must have a negative serum or urine pregnancy test prior to the first dose of study treatment\n9. Patients with active brain metastases requiring palliation with steroids not stable for at least 4 weeks post radiation therapy or surgery\n10. Leptomeningeal carcinomatosis\n11. Patients with another primary malignancy not in remission for at least 3 years. Exceptions include non-melanoma skin cancer, curatively treated localized prostate cancer with normal prostate specific antigen, low risk prostate cancer followed expectantly, resected stage 1 colon cancer, resected stage 1 breast cancer, cervical carcinoma in situ on biopsy, melanoma in situ resected, or squamous intraepithelial lesion on PAP smear.","99 Years",{"count":49,"type":20},72,[51],"PHASE1","The purpose of the research is to determine the highest dose of an oral compound called zeaxanthin that can be safely taken each day in patients with advanced cancer, the toxicity profile of zeaxanthin, and the dose of zeaxanthin to use in future cancer clinical trials.",[26,54],"Metastatic Solid Tumor","2026-06-03",{"date":57,"type":31},"2026-06-05",{"date":59,"type":31},"2022-04-17",{"date":61,"type":20},"2028-03",{"name":63,"class":64},"Valley Health System","OTHER",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":77,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":65},"100446706","unc-childhood-adolescent-and-young-adult-cancer-cohort-100446706","NCT05096923","UNC Childhood, Adolescent, and Young Adult Cancer Cohort","UNC-CAYACC","Inclusion Criteria:\n\n* Patient ages 0-39 years at the time of cancer diagnosis (ages 1-39 years at enrollment) who are at any point in treatment and survivorship trajectory\n* English or Spanish speaking\n\nExclusion Criteria:\n\n* Unwilling to sign informed consent\n* Speak a language other than English or Spanish.","1 Year","39 Years",{"count":76,"type":20},500,"30 Years","OBSERVATIONAL","Purpose: This study aims to create a registry of childhood, adolescent, and young adult patients with cancer (\\\u003C40 years-old at cancer diagnosis), entitled the 'UNC Childhood, Adolescent, and Young Adult Cancer Cohort' (UNC-CAYACC). This resource will serve to support cancer outcomes research among pediatric and young adult cancer patients with a primary focus on enrolling patients treated as adolescents or young adults (AYAs, 15-39 years).\n\nProcedures: As appropriate for age, participants will complete physical and cognitive functional assessments; questionnaires to assess health-related quality of life and other patient-reported outcomes; will undergo body composition and anthropometric measurements; and will be asked to provide biospecimens for biobanking. Assessments will be collected (as possible) at diagnosis, during active treatment, following treatment completion, and annually in survivorship to assess outcomes throughout the treatment and survivorship trajectory. Sociodemographic and clinical information such as cancer treatment modalities and cumulative doses will be collected by medical record abstraction. Participants will be eligible to enroll at any time from diagnosis through survivorship. This registry will provide data to better understand the manifestations of accelerated aging and key contributing factors among children, adolescents, and young adults with cancer.",[81,82,26,83],"Pediatric Cancer","Cancer","Survivorship",[85,86],"Adolescent and young adult","AYA","2026-05-08",{"date":89,"type":31},"2026-05-12",{"date":91,"type":31},"2021-12-17",{"date":93,"type":20},"2031-12-31",{"name":95,"class":64},"UNC Lineberger Comprehensive Cancer Center",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100639231","phase-1-safety-tolerability-and-preliminary-antitumor-activity-of-cationic-peptide-il22bp-mrna-in-advanced-solid-tumors-100639231","NCT07583654","Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors","A Clinical Trial of Cationic Peptide-IL22BP mRNA for Safety, Tolerability, and Preliminary Antitumor Activity in Patients With Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n* Male or female patients aged ≥18 years and ≤70 years.\n* Histopathologically confirmed advanced recurrent\u002Fmetastatic malignant solid tumors that are refractory to second-line treatment and have no available standard clinical therapeutic options (e.g., advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, malignant melanoma, etc.).\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n* Expected overall survival ≥3 months.\n* Interval from the last chemotherapy, radiotherapy, or surgery ≥28 days.\n* Interval from the last use of nitrosourea or mitomycin C ≥6 weeks.\n* Adequate organ function, defined by the following laboratory parameters within 14 days prior to enrollment:\n* Hemoglobin ≥90 g\u002FL (no blood transfusion within 14 days).\n* Absolute neutrophil count \\>1.5 × 10⁹\u002FL.\n* Platelet count ≥80 × 10⁹\u002FL.\n* Total bilirubin ≤1.5 × upper limit of normal (ULN).\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5 × ULN (≤5 × -ULN in case of liver metastasis).\n* Creatinine clearance ≥60 mL\u002Fmin (calculated by Cockcroft-Gault formula).\n* Left ventricular ejection fraction (LVEF) ≥50%.\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Participation in another investigational drug clinical trial within 4 weeks.\n* Tumor located adjacent to major blood vessels or trachea.\n* Uncontrolled cardiac clinical symptoms or diseases, including New York Heart Association (NYHA) Class ≥2 heart failure, unstable angina, myocardial infarction within 1 year, or clinically significant supraventricular\u002Fventricular arrhythmias requiring treatment or intervention.\n* Female patients who are pregnant or lactating.\n* Active pulmonary tuberculosis, bacterial or fungal infection (≥Grade 2 per NCI-CTCAE version 5.0), active human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection.\n* History of uncontrollable psychoactive substance abuse or presence of mental disorders.\n* Any active autoimmune disease or history of autoimmune disease, including but not limited to uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism.\n* Subjects with vitiligo or childhood asthma in complete remission (no adult intervention required) are eligible; subjects with asthma requiring bronchodilator therapy are excluded.\n* Receiving immunosuppressive therapy.\n* History of drug abuse or known medical, psychological, or social conditions that interfere with study compliance (e.g., alcoholism or illicit drug addiction).\n* Known hypersensitivity, allergy, or intolerance to the study drug CPIL22BP mRNA (including any excipients), or history of severe allergic reactions to any drugs, foods, or vaccines (e.g., anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, local Arthus reaction, etc.).\n* Female subjects planning pregnancy, or male subjects whose partner plans pregnancy, from screening until 12 months after the last study drug injection.\n* Any concomitant disease that, in the investigator's judgment, may seriously compromise patient safety or prevent the subject from completing the study.","70 Years",{"count":105,"type":20},18,[51],"The goal of this phase 1 clinical trial is to evaluate the safety, tolerability, and preliminary antitumor activity of a peptide-delivered IL-22BP biotherapy in patients with advanced solid tumors. The main questions it aims to answer are:\n\nIs the IL-22BP formulation safe and tolerable? Does the IL-22BP formulation show preliminary antitumor activity?",[109,110,111,26],"mRNA Vaccine","Solid Tumor Cancer","Peptides",[113,114,115,116],"mRNA vaccine","Cancer metastasis","Solid tumor","IL-22","NOT_YET_RECRUITING","2026-05-06",{"date":120,"type":31},"2026-05-13",{"date":122,"type":20},"2026-05-30",{"date":124,"type":20},"2027-12-30",{"name":126,"class":64},"West China Hospital",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":144,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":158},"100396514","phase-1-an-open-label-study-of-inv-1120-as-a-single-agent-and-in-combination-with-pembrolizumab-in-adult-patients-with-advanced-solid-tumors-100396514","NCT04443088","An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors","A Phase 1a\u002F1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors","KEYNOTE-E12","Inclusion Criteria:\n\n1. Written informed consent, according to local guidelines, signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses;\n2. Patient must be ≥18 years-of-age at the time of signature of the informed consent form (ICF);\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1;\n4. Patients with histologically or cytologically confirmed advanced solid tumors which have progressed on or following standard therapy or for which no standard therapy exists;\n5. Patients with life expectancy ≥3 months;\n6. Patients with at least one measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI), according to RECIST v1.1. Tumor lesions that have been irradiated ≥4 weeks before the start of treatment, and have subsequently had documented progression, may be chosen as target lesions in the absence of measurable lesions that have not been irradiated;\n7. Patients whose laboratory data at screening meet the acceptable criteria for bone marrow, liver function and renal function.\n8. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test during screening. A woman is considered of childbearing potential (fertile) following menarche and until becoming postmenopausal unless permanently sterile. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Postmenopausal women can be included;\n9. Male patients with female partners of childbearing potential and female patients of childbearing potential are required to use two forms of acceptable contraception, including one barrier method, during their participation in the study and for 3 months following last dose. Medically acceptable contraception includes:\n\n   * Hormonal methods (Needs to have been instituted at least 1 month prior to the first dose of study drug):\n   * Barrier methods:\n   * Abstinence, defined as refraining from sexual intercourse\n10. Male patients must also refrain from donating sperm from the first dose of study drug until 4 months after the last dose of study drug;\n11. Patients must be able to swallow and retain orally administered medication.\n\nExclusion Criteria:\n\n1. History (≤5 years) or current evidence of cancer that is histologically distinct from the cancer under study, except for cervical carcinoma in situ, superficial non-invasive bladder tumors, or curatively treated Stage I non-melanoma skin cancer. Patients with hepatocellular carcinoma will be excluded from Phase 1b dose escalation;\n2. Known serious allergy to investigational drug or excipients (microcrystalline cellulose);\n3. History of severe autoimmune disease (including significant ongoing immune-related adverse events of prior immune-oncology therapy) or autoimmune disorder that requires chronic systemic corticosteroid treatment at immunosuppressive doses (prednisone \\>10 mg\u002Fday or equivalent);\n4. Known malignant central nervous system disease other than neurologically stable, treated brain metastases - defined as metastases having been treated by surgery, surgery plus radiotherapy or radiotherapy alone, with no evidence of progression or hemorrhage and off any systemic corticosteroids for at least 4 weeks prior to signing the consent;\n5. History (within 4 weeks of starting treatment) or evidence of active infections (Grade ≥2);\n6. Seropositive status for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at any time before the start of treatment: Testing for seropositive status during screening will be at the discretion of the Investigator in patients without previously reported results;\n7. History or evidence of any severe and\u002For uncontrolled medical conditions or other conditions that, in the opinion of the Investigator and Sponsor, could affect the patient's participation in the study, such as any disorder or surgical procedure that could impact the absorption of study drug from the gastrointestinal tract.\n8. History (≤6 months before the start of treatment) or evidence of any of the following: acute myocardial infarction, unstable angina pectoris, coronary artery bypass graft, cerebrovascular accident, or transient ischemic attack;\n9. Patients who have impaired cardiac function or clinically significant cardiac diseases, including any of the following:\n\n   * Congenital long QT syndrome;\n   * Significant ventricular or supraventricular arrhythmias (patients with sinus arrhythmia or chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible);\n   * LVEF \\\u003C 50% by ECHO or MUGA;\n   * Other clinically significant heart disease such as known congestive heart failure New York Heart Association (NYHA) Class III-IV;\n10. Patients with QT interval ≥470 msec in females and ≥450 msec in males at screening using Fridericia's formula (determined as the mean of 3 QTcF values from the screening triplicate ECG obtained with adequate quality);\n11. Women who are pregnant or breastfeeding.\n12. WOCBP and sexually active fertile men with WOCBP partners who are unwilling or unable to use acceptable contraception method to avoid pregnancy for at least 1 month before the first dose of the study drug, during the study, and for 4 months after the last dose of study drug;\n13. Male patient who plans to father a child while enrolled in this study or within 4 months after the last dose of study drug;\n14. Not recovered from toxicity from prior anticancer therapy to baseline or Grade 1 (except toxicities which are not clinically significant such as alopecia, skin discoloration).\n15. History of an allogeneic bone marrow or solid organ transplant;\n16. Use of systemic anti-cancer agent (except luteinizing hormone-releasing hormone (LHRH) agonists, bisphosphonates and denosumab) or investigational drug ≤28 days or five half-lives whichever is shorter prior to the first dose of study treatment;\n17. Radiation therapy ≤28 days prior to the first dose of study treatment, or likely to require radiation therapy at any time until the 30 days after the last dose of study treatment, except for palliative radiation therapy limited to non-target bone lesions;\n18. Major surgery within 4 weeks before enrollment or surgery with ongoing post-operative complications);\n19. History of transfusion of platelets ≤2 weeks before the start of treatment;\n20. Patients who start erythropoietin or granulocyte-colony stimulating factor (G-CSF), pegfilgrastim, or filgrastim ≤3 weeks before screening;\n21. Patients taking medications known to have a significant risk of causing Torsades de Pointes. Patients who have discontinued any of these medications must have a wash-out period of at least 7 days or at least 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug.\n22. History of use of H2 blockers (\\\u003C24 hours before the first dose of study treatment and during the study) and proton pump inhibitors (\\\u003C5 days before the first dose of study treatment and during the study).\n23. Patients with recent (within past 12 months) history, or are currently being treated for gastroesophageal ulcer.\n\n    The following additional exclusion criteria will apply to patients enrolling in Phase 1b:\n24. Have been discontinued treatment due to a Grade 3 or higher immune-related (irAE) from prior anti-PD-1 or anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137) (only for dose expansion).\n25. Patient is currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of administration of investigational products.\n26. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Note: Administration of killed vaccines are allowed.\n27. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of its excipients.\n28. Has a history of (non-infectious) pneumonitis \u002F interstitial lung disease that required steroids or has current pneumonitis \u002F interstitial lung disease or radiation pneumonitis.",{"count":136,"type":20},78,[51],"Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.",[82,140,26,141,142,143],"Solid Tumor, Adult","Solid Carcinoma","Solid Tumor, Unspecified, Adult","Tumor, Solid",[145,146,82,147],"Ionova","Ionova Bio","Oncology","2026-03-16",{"date":150,"type":31},"2026-03-18",{"date":152,"type":31},"2020-06-26",{"date":154,"type":20},"2026-12-31",{"name":156,"class":157},"Shenzhen Ionova Life Sciences Co., Ltd.","INDUSTRY",3,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":166,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":65},"100627902","phase-1-trastuzumab-deruxtecan--stereotactic-radiosurgery-srs-in-her2-breast-cancer-brain-metastases-100627902","NCT07454668","Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases","Phase 1 Trial of Trastuzumab Deruxtecan With Stereotactic Radiosurgery (SRS) in Participants With Brain Metastases From HER-2 Positive Breast Cancer","Inclusion Criteria:\n\n1. Histologically confirmed HER-2-positive breast cancer with newly diagnosed brain metastases.\n2. ECOG Performance Status (PS) of 0, 1, 2.\n3. Participants with 1-10 brain metastases will be candidates for T-DXd with SRS at the discretion of the treating radiation oncologist. Intra-cranial metastasis must measure 3 cm or less in the greatest dimension.\n4. Age ≥ 18 years\n5. Signed written informed consent by patient or legally authorized representative. A signed informed consent must be obtained prior to any study-specific procedures.\n6. Life expectancy of at least 12 weeks.\n7. Any number of prior systemic therapies will be allowed, except T-DXd.\n8. Hemoglobin ≥ 9 g\u002FdL, White blood count ≥ 3.0 × 109\u002FL, Absolute Neutrophil count ≥ 1.5 × 109\u002FL and platelet count ≥ 100 × 109\u002FL.\n9. Serum bilirubin ≤ 1.5 × upper limit of normal (ULN).\n10. AST and\u002For ALT ≤ 2 × ULN (≤ 5 × ULN when clearly attributable to the presence of liver metastases).\n11. Serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance \\> 60 mL\u002Fmin.\n12. Ability to comply with study procedures and monitoring.\n13. For individuals of childbearing potential, a negative pregnancy test should be obtained within 7 days prior to the start of therapy.\n14. Participants must have left ventricular ejection fraction (LVEF) ≥ 50% by either an echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within 28 days before enrollment (to be assessed as clinically indicated).\n15. Male or female participants of reproductive potential need to employ two highly effective and acceptable forms of contraception throughout their participation in the study and for 7 months after last dose of T-DXd.\n\nHighly effective and acceptable forms of contraception are:\n\n* Male condom plus spermicide\n* Cap plus spermicide\n* Diaphragm plus spermicide\n* Copper T\n* Progesterone T\n* Levonorgestrel-releasing intrauterine system (e.g., Mirena®)\n* Implants\n* Hormone shot or injection\n* Combined pill\n* Mini-pill\n* Patch\n\nPostmenopausal individuals on the study (that will not need contraception) is defined as:\n\n* Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments.\n* LH and FSH levels in the postmenopausal range for individuals \\\u003C 50 years.\n* Radiation-induced oophorectomy with last menses \\> 1 year ago.\n* Chemotherapy-induced menopause with \\> 1 year interval since last menses.\n* Surgical sterilization (bilateral oophorectomy or hysterectomy).\n\nMen and women and members of all races and ethnic groups are eligible for this trial.\n\nExclusion Criteria:\n\n1. Participants with leptomeningeal metastases documented by MRI or CSF evaluation.\n2. Evidence of intra-tumoral or peri-tumoral hemorrhage deemed clinically significant by the treating physician.\n3. Brain metastases within 5 mm of the optic chiasm or optic nerve.\n4. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom, e.g., Crohn's disease, malabsorption, or CTCAE grade \\> 2 diarrhea of any etiology at baseline.\n5. History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, New York Heart Association (NYHA) functional classification of 3 or 4.\n6. Unable to undergo brain MRI.\n7. Screen for human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C. HIV\u002FHBV\u002FHCV testing per institutional practice.\n8. All toxicities from prior therapies must have resolved to CTCAE v5.0 grade 1 or better by the time of study enrollment.\n9. Other concurrent severe and\u002For uncontrolled concomitant medical conditions (e.g., active, or uncontrolled infection, uncontrolled diabetes, second active malignancy) that could cause unacceptable safety risks or compromise compliance with the protocol.\n10. Currently receiving other investigational cancer therapy (with the exception of continuing therapy with GnRH analogues) within 4 weeks prior to start of study treatment.\n11. Mean QT interval corrected heart rate (QTc) ≥ 470 ms calculated from 3 electrocardiograms using Fredericia's Correction, calculated as: 8.22 ∛(RR interval)\n12. LVEF \\\u003C50%.\n13. Ineligible for treatment with T-DXd.\n14. Ineligible for treatment with SRS.\n15. Active or prior documented ILD\u002Fpneumonitis or suspected ILD\u002Fpneumonitis that cannot be ruled out by imaging at screening.\n16. History of hypersensitivity to T-DXd.\n17. History and\u002For confirmed corneal ulceration.\n18. Pregnant or breast feeding. The patients should not breast feed for 7 months after stopping the drug.\n19. Use of anthracyclines will be prohibited while on the protocol.\n20. Prior cranial radiation is not allowed.","FEMALE",{"count":168,"type":20},20,[51],"A phase I clinical trial (a type of research study) for people with human epidermal growth factor receptor 2 (HER-2) positive breast cancer with metastasis to the brain. This research study will evaluate how well brain metastases can be controlled using a type of radiation therapy known as stereotactic radiosurgery (SRS) when combined with the therapeutic agent Trastuzumab Deruxtecan (T-DXd). The combined use of SRS with T-DXd is considered investigational.",[172,173,174,82,26],"Breast Cancer","HER2-positive Breast Cancer","Brain Metastases","2026-03-02",{"date":177,"type":31},"2026-03-06",{"date":179,"type":20},"2026-06",{"date":181,"type":20},"2029-07",{"name":183,"class":64},"Baptist Health South Florida",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":21,"phases":194,"briefSummary":196,"conditions":197,"keywords":200,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":4},"100624894","symptom-management-and-survivorship-plus-coaching-for-advanced-cancer-survivors-and-their-caregivers-100624894","NCT07415564","Symptom Management and Survivorship Plus Coaching for Advanced Cancer Survivors and Their Caregivers","Symptom Management and Survivorship Plus Coaching to Reduce Symptom Severity and Improve Health Related-quality of Life (HR-QOL) for Breast, GI and Melanoma Cancer Survivors and Their Caregivers","SMSH and SMSH+","Inclusion criteria for cancer survivors:\n\n* Age 18 or older\n* Diagnosed with metastatic or stage IV breast, gastrointestinal (GI), and melanoma cancer\n* Able to perform basic activities of daily living\n* Cognitively oriented to time, place, and person (recruiter determined)\n* Able to speak and understand English or Spanish\n* Access to a telephone\n* Has a caregiver in any relationship role (e.g., spouse, sibling, parent, friend) who can.\n\nInclusion criteria for the caregivers:\n\n* Age 18 or older\n* Able to speak and understand English or Spanish\n* Telephone access\n* Not currently treated for cancer\n\nExclusion criteria:\n\n* Nursing home resident\n* Bedridden\n* Hospice care\n* Currently receiving a symptom management intervention",{"count":193,"type":20},200,[195],"NA","The protocol will include a 10-week Symptom Management and Survivorship Handbook (SMSH) intervention to address informational needs for the management of physical and psychological symptoms, bundled with telephone delivered health coaching to address their symptom interference with physical, psychological and social functioning. The SMSH intervention, which includes both symptom assessment and management, is simple to implement, scalable, and evidence-based will be delivered to all survivors and caregivers (dyads) in this study, and will serve as an active control. In addition to the SMSH, intervention arm dyads will receive health coaching to address symptom interference and reduce social isolation. Symptom burden is more pronounced in marginalized populations such as Latina\u002Fo, rural, older age survivors and their caregivers.18-20 Many health disparities in these populations are underwritten by social isolation due to lack of access, disconnection from linguistically competent health care, mobility, and geographic proximity,21-23 and health coaching can address these issues.\n\nThe specific aims of the proposed feasibility study are to determine among survivors with metastatic or stage IV cancer and their caregivers (dyads):\n\nAim 1: Demonstrate SMSH plus health coaching feasibility (recruitment, retention, satisfaction (acceptability and appropriateness) for cancer survivors and their caregivers. Benchmarks: Recruitment 70% approached, Retention 75%, and participant satisfaction through qualitative exit interviews in week 11.\n\nAim 2: Collect preliminary data for the intervention impact on whether the SMSH + health coaching results in lowered burden of 24 symptoms (primary outcome) over weeks 1-10, and improved HRQoL (social, physical, psychological) (secondary outcome) at week 11, compared to SMSH alone.\n\nAim 3. Examine the enactment of self-management strategies in SMSH+health coaching versus SMSH alone.\n\nThe proposed pilot trial will provide proof of concept for the SMSH coupled with a live telephone delivered health coaching intervention to improve symptom management and HRQoL for metastatic breast, GI, and melanoma cancer survivors and caregivers. By addressing physical and psychological symptoms and survivorship using scalable, accessible interventions delivered via telephone, within reach of traditionally underserved populations, the findings have the potential to lay the foundation for the dissemination and implementation of a practical solution to meet survivor-caregiver needs both locally and nationally.",[26,198,199],"Symptoms and Signs","Quality of Life",[201,202,203,204,205],"cancer","Metastatic cancer","Symptom management","Cancer survivorship","Cancer caregivers","2026-02-09",{"date":208,"type":31},"2026-02-17",{"date":210,"type":20},"2026-03-01",{"date":212,"type":20},"2027-09-01",{"name":214,"class":64},"University of Arizona",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":16,"minAge":222,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":65},"100427150","illuminoss-photodynamic-bone-stabilization-system-for-the-treatment-of-impending-and-actual-pelvis-fractures-100427150","NCT04842266","IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures","A Prospective Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Pelvis From Metastatic Bone Disease or Geriatric Pelvic Fractures","Inclusion criteria:\n\nPatients are being targeted because they have already agreed to the undergo the IlluminOss Pelvic Implant for standard clinical care. It is a decision made by the treating surgeon separately from research and prior to mention of the study.\n\n1. Patient is a skeletally mature patient 21 years of age or older (closed epiphyseal plates) who receiving the FDA-approved IlluminOss Pelvic Implant\n2. IlluminOss Pelvic Implant is intended to treat pain due to impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis secondary to metastatic malignancy, multiple myeloma, lymphoma, or radiation osteitis or a pelvic fragility fracture in a geriatric patients (age 65 or older)\n3. VAS Pain Score ≥ 30 on 0 to 100 scale\n\nExclusion criteria:\n\n1. Patient is uncooperative, or patient incapable of following directions (for example, as a consequence of a neurological or psychiatric disorder)\n2. Patient is a prisoner\n3. Patient is deemed surgically unfit by the medical oncology service","21 Years",{"count":224,"type":20},100,"The aim of this project is to assess the effectiveness of the IlluminOss pelvic implants in patients with pelvic metastatic disease presenting with pain, risk of pathologic fracture, non-displaced or minimally displaced pathologic fracture of the pelvis, and geriatric patients with pelvic fragility fractures. Results from this study will be used to confirm preliminary clinically and possibly statistically significant reductions in pain and improvements in function among these patients.",[26,227,228],"Trauma","Pathologic Fracture","2026-01-14",{"date":231,"type":31},"2026-01-16",{"date":233,"type":31},"2021-11-18",{"date":235,"type":20},"2027-12",{"name":237,"class":64},"Massachusetts General Hospital",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":244,"targetDuration":246,"studyType":78,"phases":4,"briefSummary":247,"conditions":248,"keywords":290,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100320510","synergy-ai-artificial-intelligence-based-precision-oncology-clinical-trial-matching-and-registry-100320510","NCT03452774","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","Inclusion Criteria:\n\n* Pts with solid and hematological malignancies;\n* Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2\u002FNeu, Tumor mutational burden\u002Fload (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A\u002FB, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1\u002F2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA\u002FB\u002FC, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.\n\nThese biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform\n\n* Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and\u002For patient\n\nExclusion Criteria:\n\n* ECOG PS \\> 2;\n* Abnormal organ function;\n* Hospice enrollment",{"count":245,"type":20},50000,"36 Months","International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.",[249,82,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,172,282,283,284,285,286,287,288,289],"Cancer, Metastatic","Cancer of Pancreas","Cancer of Liver","Cancer of Stomach","Cancer Liver","Cancer of Rectum","Cancer of Kidney","Cancer of Esophagus","Cancer of Cervix","Cancer of Colon","Cancer of Larynx","Cancer, Lung","Cancer, Breast","Cancer, Advanced","Cancer Prostate","Cancer of Neck","Cancer of Skin","Neuroendocrine Tumors","Carcinoma","Mismatch Repair Deficiency","BRCA Gene Rearrangement","Non Hodgkin Lymphoma","Leukemia","Non Small Cell Lung Cancer","Cholangiocarcinoma","Glioblastoma","Central Nervous System Tumor","Melanoma","Urothelial Carcinoma","Bladder Cancer","Ovarian Cancer","Endometrial Cancer","Testicular Cancer","COVID","Myelofibrosis","Myeloproliferative Neoplasm","Myeloproliferative Disorders","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Myelodysplastic Syndromes",[291,292,293,294,295,296,297,298,299,300,301,201,302,303,304],"artificial intelligence","virtual tumor board","clinical trial","clinical trial matching","electronic medical record","machine learning","cost of care","targeted therapy","immunotherapy","precision medicine","precision oncology","value based care","real world data","data analytics","2025-10-25",{"date":307,"type":31},"2025-10-28",{"date":309,"type":31},"2018-01-01",{"date":311,"type":20},"2040-06",{"name":313,"class":157},"Massive Bio, Inc.",68,{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":323,"targetDuration":73,"studyType":78,"phases":4,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":336},"100541988","the-italian-registry-of-malnutrition-in-oncology-100541988","NCT06337019","The Italian Registry of Malnutrition in Oncology","Multicentric, Observational, Longitudinal Study for the Evaluation of Nutritional Management Implications in Newly Diagnosed Italian Cancer Patients: The Italian Registry of Malnutrition in Oncology (IRMO)","IRMO","Inclusion Criteria:\n\n* Aged ≥18 years;\n* New diagnosis of the following cancers: head and neck, oesophagus\u002Fstomach, colorectal, hepato-biliary, pancreatic, lung, prostate, other urogenital, breast, gynaecological and, soft tissue sarcomas and melanomas; patients with a new diagnosis of metastatic disease will be also included;\n* Eligible for active treatment;\n* Written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Impossibility to undertake the expected measurements;\n* Impossibility to guarantee the attendance of the follow-up visits.",{"count":324,"type":20},1500,"The aim of the Italian Registry of Malnutrition in Oncology (IRMO) is to set up a digital register of newly diagnosed or treated oncologic patients to monitor their nutritional status, early identify malnutrition and investigate the implications of nutritional support management. In particular, this project aims to establish a prospective cohort of cancer patients in order to investigate the effects of nutritional status and management on overall survival (OS) and progression free survival (PFS), and analyse the effects of the nutritional management and support on patients' symptoms and QoL.",[82,26],"2024-04-02",{"date":329,"type":31},"2024-04-03",{"date":331,"type":31},"2022-10-25",{"date":333,"type":20},"2027-10",{"name":335,"class":64},"Fondazione IRCCS Policlinico San Matteo di Pavia",16,{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":21,"phases":346,"briefSummary":348,"conditions":349,"keywords":350,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":4},"100542040","phase-2-verify-vedolizumab-for-the-prevention-of-immune-checkpoint-inhibitor-related-diarrhea-or-colitis-in-patients-with-cancer-100542040","NCT06337695","VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer","VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer: A Randomized, Double-Blinded, Placebo Controlled Trial","Inclusion Criteria:\n\n* Signed informed consent prior to initiation of any study specific activities or procedures\n* Diagnosed with unresectable advanced stage III or metastatic stage IV malignancy\n* Planned for initiation of SOC immunotherapy and development of prognostic biomarker evidence that predisposes to ICI diarrhea\u002Fcolitis risk\n* Ability to and willingness to adhere to the randomized treatment interventions (vedolizumab or placebo), administered intravenously\n\nExclusion Criteria:\n\n* Condition(s) for which vedolizumab is contraindicated (e.g., hypersensitivity reaction, known allergic reaction to vedolizumab or its components)\n* Current or prior use of vedolizumab or prior immunotherapy exposure for cancer\n* Presence of inflammatory bowel disease (Crohn's disease, ulcerative colitis), indeterminate colitis, or microscopic colitis\n* Presence of ileostomy, colostomy, or short bowel syndrome\n* Presence of known luminal gastrointestinal metastases at baseline\n* Presence of significant pre-existing autoimmune disease (at investigator's discretion)\n* Presence of severe infection(s) or opportunistic infection(s)\n* Active enteric infection with viral, bacterial, or parasitic pathogens\n* Presence of untreated latent or active tuberculosis, or untreated chronic hepatitis B virus\n* Baseline ECOG status grade ≥3\n* Pregnancy or lactation\n* Treatment with another investigational product within 8 weeks of randomization\n* Requirement for baseline anti-diarrheal treatment(s) (including but not limited to loperamide, diphenoxylate-atropine, octreotide, tincture of opium), anticholinergic drug(s), or opioid-based analgesic(s) used specifically for diarrhea control within 14 days of randomization\n* Any condition or diagnosis, that could in the opinion of the Qualified Investigator or delegate interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk",{"count":345,"type":20},298,[347,23],"PHASE2","The purpose of this study is to assess the prevention of immune checkpoint inhibitors (ICIs) related diarrhea\u002Fcolitis using vedolizumab in participants with unresectable stage III or metastatic stage IV cancer, starting standard of care (SOC) immunotherapy",[82,26],[351],"Immune Checkpoint Inhibitors","2024-04-01",{"date":327,"type":31},{"date":355,"type":20},"2024-07-01",{"date":357,"type":20},"2026-12-01",{"name":359,"class":64},"University of Calgary",{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":16,"minAge":368,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":21,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":383},"100425285","phase-2-improving-public-cancer-care-by-implementing-precision-medicine-in-norway-100425285","NCT04817956","Improving Public Cancer Care by Implementing Precision Medicine in Norway","Improving Public Cancer Care by Implementing Precision Medicine in Norway A Multi-cohort Phase 2 Treatment Clinical Study Investigating Efficacy of Approved Drugs Outside Indication in Patients With Advanced Cancer","IMPRESS-N","Inclusion Criteria:\n\n* Type of Participant and Health status\n\n  1. Patient with a pathology-proven locally advanced or metastatic malignant disease who is no longer benefitting from standard anti-cancer treatment or for whom, in the opinion of the investigator, no such treatment is available or indicated.\n  2. ECOG performance status 0-2.\n  3. For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.\n  4. Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion\u002Fexclusion criteria specified in the drug-specific study manuals for each agent will take precedence for this and all inclusion criteria (exceptions for haematological diagnoses):\n\n     1. Absolute neutrophil count ≥ 1.5 x109 \u002F L\n     2. Hemoglobin \\> 9 g\u002Fdl\n     3. Platelets \\> 75,000\u002Fµl\n     4. Total bilirubin \\\u003C 1.5 x institutional upper limit of normal (ULN)\n     5. AST (SGOT) and ALT(SGPT) \\\u003C 2.5 x institutional upper limit of normal (ULN) (or \\\u003C 5 x ULN in patients with known hepatic metastases)\n     6. Calculated or measured creatinine clearance ≥ 40 mL\u002Fmin\u002F1.73 m2.\n  5. Patients must have measurable or evaluable disease. RECIST v1.1 (10, 18) will be used for patients with solid tumours. For patients with multiple myeloma or non-Hodgkin lymphoma, IMWG response criteria (19) and CHESON\u002FLugano guidelines (20) will be used, resp. For glioblastoma patients, RANO criteria will be used (21). iRECIST will be used for immunotherapy-cohorts. IWG response criteria will be used for haematological cancers.\n\n     Patients whose disease cannot be objectively measured by physical or radiographic examination (e.g., elevated serum tumour marker only) are NOT eligible, with the exception of CA-125 for ovarian cancer and PSA for prostate cancer (22).\n  6. Results must be available from a genomic \u002F molecular test performed in a preapproved laboratory (Section 10.15). The test used to qualify a patient for participation in IMPRESS-Norway may have been performed on any specimen of the patient's tumour obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma (\"liquid biopsies\") will also be acceptable if the genomic analysis is performed as defined in Section 10.5. NGS analyses will be performed on a newly sampled biopsy if possible. Information from these analyses might be used upon progression, for evaluation of possible new cohort-inclusion.\n  7. Have a genomic profile for which treatment with one of the approved targeted anti-cancer therapies included in this study has potential clinical benefit see Section 4.3.5\n\n     Note: Eligible genomic tests may include any of the following technologies and equivalent techniques: Immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR) (incl nanostring), array-based copy number analysis (CNV), sanger sequencing (SS), RNA sequencing, gene panels or whole exome sequencing (WES) by next generation sequencing (NGS). The test may have been performed on a fresh (frozen or in RNA-later) or paraffin-embedded specimen of the primary tumour or a metastatic deposit or on cell-free DNA derived from liquid biopsies (like for instance peripheral blood plasma), as determined by the treating physician, and must reveal a potentially actionable genomic variant or protein overexpression as defined in Section 4.3.\n  8. Patients must meet drug-specific eligibility requirements for the drug selected by the investigator.\n\nSex and Contraceptive\u002FBarrier Requirements 9.8. Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate highly effective methods of contraception for the duration of study participation, and for 4 to 24 months following completion of study therapy as defined in Section 11.4.\n\n10.9. Female participants must have a negative highly sensitive pregnancy test \\\u003C1 month prior to inclusion.\n\n11.10. Male patients should avoid impregnating a female partner. Male study patients must agree to one of the following: practice effective barrier contraception as described under sec. 11.4 during the entire study treatment period and through a certain time after the last dose of study drug. Details are given in the \"Drug specific amendment\".\n\nInformed Consent 12.11. Ability to understand and the willingness to sign a written informed consent\u002Fassent document as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Guardians \u002F parents can act on behalf of children.\n\nExclusion Criteria:\n\nA potential participant who meets any of the following criteria will be excluded from participation in this study (other exclusion criteria might apply for specific drugs).\n\nMedical Conditions\n\n1. Patients eligible to enter other ongoing trials which have to potential to benefit the patients equally or more than a IMPRESS-Norway cohort, and for whom access to the ongoing trials is manageable (taking geography into consideration).\n2. Ongoing toxicity \\> CTCAE grade 2, other than peripheral neuropathy, related to anti-tumour treatment that was completed within 4 weeks prior to treatment initiation. Patients with ongoing peripheral neuropathy of ≥ CTCAE grade 3.\n\n   Patients with known progressive brain metastases determined by serial imaging or declining neurologic function in the opinion of the treating physician. Patients with previously treated \u002F stable brain metastases are eligible. Additional exclusion criteria specific for GBM patients:\n\n   a. Patients who require anti-convulsant therapy must be taking non-enzyme inducing antiepileptic drugs (non-EIAED). EIAED are prohibited. Patients previously on EIAED must be switched to non-EIAED at least 2 weeks prior to randomization.\n3. Patients with the following pre-existing cardiac conditions, uncontrolled angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure.\n4. Patients with left ventricular ejection fraction (LVEF) known to be \\\u003C 40%.\n5. Patients with stroke (including TIA) or acute myocardial infarction within 4 months before the first dose of study treatment\n6. Patients with acute gastrointestinal bleeding within 1 month of start of treatment\n7. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, severe psychiatric illness situations, or anticipated or planned anti-cancer treatment or surgery.\n8. Patients with known allergy\u002Fhypersensitivity to the study drug (active substance or to any of the excipients).\n\nPrior\u002FConcomitant Therapy 9. Previous treatment with the selected study drug for the same malignancy. 10. Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates) or ongoing castration-intent therapy for prostate cancer. These medications must have been started ≥ 1 month prior to enrolment on this study. Patients may be on warfarin, low molecular weight heparin or direct factor Xa inhibitors, unless such therapies are prohibited by drug-specific exclusion criteria.\n\nDiagnostic assessments 11. If the patient's tumour has a genomic variant known to confer resistance to an anti-cancer agent available in this study, the patient will not be eligible to receive that agent but will be eligible to receive other drugs available in this study if all inclusion and exclusion criteria are met for that drug.\n\nOther Exclusions 12. Female patients who are pregnant or nursing 13. Patients who do not meet drug-specific eligibility requirements for the drug selected by the investigator\n\nNote: For each drug included in this protocol, specific inclusion and exclusion criteria (based on the Summary of Product Characterics (SPC) or manufacturer's recommendations) may also apply. These can be found in the supplemental information about each agent included in the appendices. Drug-specific inclusion and exclusion criteria will take precedence over the general inclusion\u002Fexclusion criteria\n\n\\-","16 Years",{"count":370,"type":20},3000,[347],"IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as revealed by molecular diagnostics. IMPRESS-Norway is a nation-wide study and all hospitals with an oncology and \u002F or hematology department will be invited to participate in the study. The study will use a combined umbrella and basket design and a Simon two-stage model of expanding cohorts to follow up potentially effective combinations of biomarker and drug on specific indications. Sampling of biological material will be performed at presentation, during treatment and upon progression. Additional biomarker and translational analyses including whole genome sequencing (WGS) on tumour material and liquid biopsies, identifying mechanisms underlying drug sensitivity versus resistance will be performed.",[26],"2024-02-28",{"date":376,"type":31},"2024-02-29",{"date":378,"type":31},"2021-04-01",{"date":380,"type":20},"2045-04-30",{"name":382,"class":64},"Oslo University Hospital",17]